CD40 Gene Silencing Reduces the Progression of Experimental Lupus Nephritis Modulating Local Milieu and Systemic Mechanisms

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ripoll, Èlia ^a   Merino, Ana ^a   Goma, Montse ^a   Aran, Josep M ^b   Bolaños, Nuria ^a   de Ramon, Laura ^a   Herrero Fresneda, Immaculada ^a   Bestard, Oriol ^a   Cruzado, Josep M ^a   Grinyó, Josep M ^a   Torras, Juan ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; CD3 ANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; CHOLESTEROL; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA ANTIBODY; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CD40 GENE; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; EXPERIMENTAL MODEL; GENE SILENCING; GENE THERAPY; GLOMERULUS; HISTOPATHOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INTERSTITIUM; KIDNEY PARENCHYMA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PLASMA CELL; PROTEINURIA; SPLEEN CELL; TISSUE DISTRIBUTION;

ALBUMINURIA; ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD40; CELL SURVIVAL; CELLS, CULTURED; COMPLEMENT C3; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOGLOBULIN G; KIDNEY; LIPOPOLYSACCHARIDES; LUPUS NEPHRITIS; MALE; MICE; MICE, INBRED ICR; PLASMA CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPLEEN; TRANSFECTION;

ANIMALIA; MUS;

EID: 84879052497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065068     Document Type: Article

References (43)

1. Bagavant H, Fu SM, (2009) Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 21: 489-494.
2. Robson MG, Walport MJ, (2001) Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy 31: 678-685.
3. Berden JH, (2003) Lupus nephritis: consequence of disturbed removal of apoptotic cells? Neth J Med 61: 233-238.
4. Davidson A, Aranow C, (2010) Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 6: 13-20.
5. Connolly K, Roubinian JR, Wofsy D, (1992) Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol 149: 3083-3088.
6. Grewal IS, Flavell RA, (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135.
7. Davidson A, Wang X, Mihara M, Ramanujam M, Huang W, et al. (2003) Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci 987: 188-198.
8. Russell PJ, Hicks JD, Burnet FM, (1966) Cyclophosphamide treatment of kidney disease in (NZB x NZW) F1 mice. Lancet 1: 1280-1284.
9. Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, et al. (2004) Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 50: 1539-1548.
10. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, et al. (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57: 258-264.
11. Sang A, Yin Y, Zheng YY, Morel L, (2012) Animal models of molecular pathology systemic lupus erythematosus. Prog Mol Biol Transl Sci 105: 321-370.
12. Huston DP, Steinberg AD, (1979) Animal models of human systemic lupus erythematosus. Yale J Biol Med 52: 289-305.
13. Borchers A, Ansari AA, Hsu T, Kono DH, Gershwin ME, (2000) The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 29: 385-399.
14. Hahn BH, (2001) Lessons in lupus: the mighty mouse. Lupus 10: 589-593.
15. Schiffer L, Sinha J, Wang X, Huang W, von Gersdorff G, et al. (2003) Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 171: 489-497.
16. Wang X, Huang W, Mihara M, Sinha J, Davidson A, (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168: 2046-2053.
17. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB, (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114.
18. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Davila M, et al. (2010) Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 185: 1577-1583.
19. Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN, (2005) LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 106: 3114-3122.
20. Vowinkel T, Wood KC, Stokes KY, Russell J, Krieglstein CF, et al. (2006) Differential expression and regulation of murine CD40 in regional vascular beds. Am J Physiol Heart Circ Physiol 290: H631-639.
21. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, et al. (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771.
22. Choung S, Kim YJ, Kim S, Park HO, Choi YC, (2006) Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 342: 919-927.
23. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, et al. (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48: 901-904.
24. Corey DR, (2007) Chemical modification: the key to clinical application of RNA interference? J Clin Invest 117: 3615-3622.
25. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
26. Ripoll E, Pluvinet R, Torras J, Olivar R, Vidal A, et al. (2011) In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection. Gene Ther 18: 945-952.
27. Pluvinet R, Olivar R, Krupinski J, Herrero-Fresneda I, Luque A, et al. (2008) CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood 112: 3624-3637.
28. Espeli M, Bokers S, Giannico G, Dickinson HA, Bardsley V, et al. (2011) Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 22: 296-305.
29. Peters AL, Stunz LL, Bishop GA, (2009) CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 21: 293-300.
30. Klinman DM, (1990) Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J Clin Invest 86: 1249-1254.
31. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, et al. (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165: 5970-5979.
32. Shimomura Y, Mizoguchi E, Sugimoto K, Kibe R, Benno Y, et al. (2008) Regulatory role of B-1 B cells in chronic colitis. Int Immunol 20: 729-737.
33. Park YB, Lee SK, Kim DS, Lee J, Lee CH, et al. (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16: 283-288.
34. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, et al. (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181: 839-844.
35. Mosser DM, Zhang X, (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226: 205-218.
36. Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, et al. (2001) Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 31: 2726-2732.
37. Starke C, Frey S, Wellmann U, Urbonaviciute V, Herrmann M, et al. (2011) High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur J Immunol 41: 2107-2112.
38. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S, (2011) The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 49: 317-323.
39. Manderson AP, Botto M, Walport MJ, (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431-456.
40. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH, (1999) Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 162: 4336-4341.
41. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR, (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839.
42. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
43. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, et al. (2006) Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12: 988-993.